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ABSTRACT 
Introduction: Argon plasma coagulation (APC) has been used to ablate dysplastic 
and non-dysplastic Barrett’s esophagus. In this study we determined the longer term 
efficacy of APC ablation within two randomized controlled trials of APC versus 
surveillance for Barrett’s esophagus in patients in whom gastroesophageal reflux was 
controlled by either surgery (Surgical trial) or proton pump inhibitors (Medical trial). 
Methods: One hundred and twenty nine patients with Barrett’s esophagus (non-
dysplastic or low grade dysplasia) were randomized to undergo either ablation using 
APC or ongoing endoscopy surveillance. Outcomes were determined at 3 time points: 
short-term (12 months), mid-term (42-75 months) and long-term (>84 months). 
Results: Initial ablation of >95% of the Barrett’s esophagus was achieved in 61 of 63 
patients randomized to. At short-term follow-up >95% ablation persisted in 47 of 56 
patients. At mid-term follow-up this continued in 33 of 49 patients. 32 were followed 
long term, and >95% ablation of the Barrett’s esophagus was maintained in 21 of 32. 
In the control groups the length of Barrett’s esophagus reduced from a mean of 4.2 
cm to 3.1 cm at long term follow-up. High grade dysplasia (HGD) developed in 1 
patient in the APC group and 3 in the surveillance group. Low grade dysplasia 
developed in 1 in the APC group and 7 in the surveillance group. 
Conclusions: APC ablation reduced the extent of Barrett’s esophagus, and this was 
maintained in some patients at longer term follow-up. However, progression to HGD 
can still occur despite APC ablation, suggesting endoscopic surveillance is still 
required. 
KEY WORDS Barrett’s esophagus, Argon plasma coagulation, Ablation, Anti-reflux 
Surgery, Proton pump inhibitor, randomized trial 
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INTRODUCTION 
Barrett’s esophagus is the major risk factor for esophageal adenocarcinoma. In 
Western populations it is present in 1-2% of adults[1], as well as in approximately 
10% of patients with gastro-esophageal reflux disease. As some patients with 
Barrett’s esophagus develop adenocarcinoma, it is generally recommended that 
patients with known Barrett’s esophagus should undergo regular endoscopy based 
surveillance[2]. Effective control of gastro-esophageal reflux by either surgical or 
medical treatment can be followed by regression of Barrett’s esophagus in some 
patients[3], although Barrett’s esophagus and the risk of progression to cancer still 
persists in most patients, despite effective treatment of reflux[4,5]  
 
There has been interest in treatments which ablate Barrett’s esophagus mucosa, as 
removing this metaplastic columnar mucosa might reduce or eradicate the risk of 
cancer. Many methods of ablation have been described, including photodynamic 
therapy (PDT), argon plasma coagulation (APC), radiofrequency ablation (RFA), and 
endoscopic mucosal resection (EMR)[6] Whilst RFA and EMR are currently the more 
popular options, APC was used more widely in the 1990’s and early 2000’s, it has 
been shown previously to be an effective method for achieving regression of Barrett’s 
esophagus, and it is relatively cheap[7,8]  
 
In the late 1990’s we commenced 2 randomized controlled trials of APC ablation vs. 
endoscopic surveillance of Barrett’s esophagus in patients who had not progressed to 
high grade dysplasia; one trial enrolled patients with Barrett’s esophagus who had 
Archived at Flinders University: dspace.flinders.edu.au
undergone successful antireflux surgery, and the other enrolled patients with Barrett’s 
esophagus managed with proton pump inhibitor (PPI) medication. The earlier results 
from these trials have been reported previously[9-11]  and they confirmed that 
ablation using APC is feasible, irrespective of the method used to control reflux. Five 
year outcomes in a subgroup of 40 patients from the trial which enrolled patients who 
had previously undergone fundoplication confirmed that APC ablation was effective 
to 5 years, but also that some regression of Barrett’s esophagus occurred in the control 
(endoscopy surveillance only) group at 5 years follow-up[10]. Outcomes beyond 12 
months from the trial which recruited patients managed with PPIs have not been 
reported. 
 
In the current study we determined the longer term outcomes for patients enrolled in 
both trials to determine the late outcome following APC ablation of Barrett’s 
esophagus. As the 2 trial protocols were identical except for one selection criteria - 
the method used for reflux control - the data sets were combined to generate a larger 
cohort of patients randomized to ablation using APC vs. surveillance. A non-
randomized comparison of outcome differences between patients managed with PPIs 
vs. fundoplication was also undertaken to evaluate the impact of the method of reflux 
treatment on outcomes following ablation with APC and in patients undergoing 
surveillance alone. 
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METHODS 
 
The methodology for the 2 randomized trials has been previously described in 
detail[9,11]. In brief, patients presenting to either the Royal Adelaide Hospital or 
Flinders Medical Centre in Adelaide, South Australia, who were older than 18 years 
and had Barrett’s esophagus with histopathologically confirmed intestinal metaplasia, 
either without dysplasia, or with low grade dysplasia (LGD), and whose gastro-
esophageal reflux disease symptoms were fully controlled by medical or surgical 
therapy were considered for entry into one of these trials. Patients were excluded if 
they had any symptoms of reflux, evidence of inadequate control of reflux at baseline 
endoscopy, or high grade dysplasia (HGD) at baseline endoscopy biopsy, or any 
previous esophageal biopsy. Patients in whom reflux was controlled by antireflux 
surgery were entered into the “surgical” trial, and patients in whom reflux was 
controlled by PPI medication were entered into the “medical” trial. In the medical 
trial, all patients were prescribed and used high dose (40mg or higher) PPI therapy to 
control reflux. 
 
Patients were randomized 1:1 to undergo either ablation using APC (APC group) or 
continue with endoscopic surveillance (Surveillance group). All patients underwent 
initial endoscopy to assess the status of their esophagus, and eligibility/exclusion 
criteria for the trial. Randomization occurred at the time of baseline endoscopy once 
eligibility was confirmed. Patients were excluded if there was no evidence of Barrett’s 
esophagus or if ulcerative esophagitis was evident. The length of the columnar 
mucosa was measured using the Prague C and M classification, and the percentage 
involvement of the circumference of the esophagus was also determined. When 
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assessing the length of Barrett’s esophagus, the “M” component of the Prague 
classification was used for data analysis. 
 
Baseline biopsies from the esophageal mucosa were collected for conventional 
histopathology analysis using a modified Seattle protocol. Biopsy collection started 1 
cm above the gastro-esophageal junction, and then every 2 cm proximally for the full 
length of the Barrett’s esophagus. Four quadrant mucosal biopsies were taken at each 
level.  
 
If appropriate, the Barrett’s esophagus mucosa was ablated in linear lengthwise strips 
using a high-frequency electrosurgical generator coupled to an argon delivery unit 
(ERBE ICC 200/APC 300; Rymed P/L, Arndell Park, NSW). Islands of Barrett’s 
esophagus were ablated by local application of APC. An attempt was made to treat 
the complete area of Barrett’s esophagus mucosa in one session in patients with short-
segments of Barrett’s esophagus (<3 cm). In patients with longer segments, multiple 
treatment sessions were always required. After 4-6 weeks patients underwent further 
endoscopy to see if more ablation therapy was needed. This was repeated every 4-6 
weeks until there was no visible columnar epithelium, or until a maximum of 6 
treatments had been undertaken. A final assessment of the effect of ablation therapy 
was done at endoscopy 4-6 weeks after the last treatment. At this stage biopsies were 
again collected and analyzed. Biopsies were collected from the same esophageal 
levels as the original baseline biopsies, irrespective of whether the esophageal mucosa 
had a columnar or squamous appearance. 
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Follow-up endoscopy was performed in a blinded fashion, twelve months after the 
initial endoscopy (surveillance group) or completion of treatment (treatment group). 
The extent of any Barrett’s esophagus was again determined, and biopsies were then 
collected from the same levels as the baseline biopsies. Endoscopy surveillance was 
repeated annually for all groups.  
 
Outcomes were determined at short term (12 months), mid term (42-75 months) and 
long term (>84 months) follow-up. At these time points the following outcomes were 
assessed:  
1) The endoscopically visible extent of any regression of Barrett’s 
esophagus - complete = 100% regression, >95% regression (several islands 
only), or regression <95% (multiple islands or residual tongues of Barrett’s),  
2 Length of Barrett’s esophagus (including the longest tongue if not 
circumferential) 
3 Development of LGD, HGD, or esophageal cancer.  
 
Power calculations performed before commencing the trials showed that 25 patients 
in each group were required to demonstrate a 15% difference in the rate of complete 
ablation at a confidence level (2-sided) of 95%, and a power of 90%. Statistical 
analysis was undertaken using InStat version 3.1a (GraphPad Software). To evaluate 
differences between continuous variables a 2-tailed unpaired t-test was performed. 
The Chi-square test was used to analyze contingency tables. A P-value of <0.05 was 
considered to be significant. The protocols for the trials were approved by the Human 
Clinical Research Ethics Committee of the Royal Adelaide Hospital, and the Flinders 
Clinical Research Ethics Committee. 
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RESULTS 
From August 1999 to November 2009, 129 patients were enrolled in the 2 trials. The 
allocation to the groups in the 2 trials is summarized in Figure 1. In 70 patients reflux 
was controlled by a fundoplication at the time of enrolment (Surgical trial); with 37 
randomized to APC ablation and 33 to endoscopic surveillance. In 59 patients reflux 
was controlled by using PPI medication at enrolment (Medical trial); with 27 
randomized to APC ablation and 32 to endoscopic surveillance. Hence, across the 2 
trials 64 patients underwent APC ablation and 65 underwent endoscopy surveillance.  
 
While treatment was randomized, the surveillance group at 63.5 years of age was 
found to be a mean of 3.6 years older (p = 0.041). At baseline endoscopy, the length 
of Barrett’s esophagus was similar for the APC vs. surveillance groups (Table 1). In 
both the APC and the surveillance groups, LGD was present at enrolment in 3 patients 
(Table 2). 
 
APC vs. Surveillance – All patients 
Of the 64 patients allocated to APC treatment, one withdrew after the initial 
endoscopy and the first treatment session, and did not complete APC ablation (Figure 
1). The median number of ablation treatments in the remaining 63 patients was 3 
(range 1-6). The extent of Barrett’s esophagus across all time points is summarized in 
Table 3. At least 95% ablation was achieved in 61 (96.8%) patients, and complete 
endoscopic and histopathological regression was achieved in 36 patients (57.1%). 
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Short term (12 months) outcomes 
One hundred and seventeen (90.7%) patients underwent endoscopy and biopsy 12 
months after enrolment. In the APC group, 8 (12.5%) patients did not undergo 
endoscopy at 12 months. Two of these were withdrawn from the trial due to ill health, 
3 died from unrelated causes during follow-up (2 of respiratory disease and 1 of a 
myocardial infarct), 1did not tolerate this endoscopy, 1 refused endoscopy and 1 
failed to attend scheduled follow-up (but returned for later follow-up). In the 
surveillance group, 4 (6.2%) patients did not undergo endoscopy; 1 refused, 2 did not 
undergo endoscopy for unknown reasons, and 1 was determined to be inappropriately 
enrolled in the trial as Barrett’s esophagus was not confirmed at baseline endoscopy.  
 
Of the 56 patients undergoing endoscopy in the APC group, 47 (83.9%) had 
regression of at least 95% of their Barrett’s esophagus, vs. 2 (3.3%) of 61 in the 
surveillance group (p<0.0001). The length of Barrett’s esophagus decreased 3.5 cm in 
the APC group (p<0.0001), but the average length was unchanged for the surveillance 
group (p=0.871) (Table 1). In the APC group LGD was not found at short term 
follow-up in any patients (Table 2). In the surveillance group LGD resolved in 1 
patient, but 2 others developed new LGD. No patient had HGD at twelve months 
follow-up. 
 
Mid-term (42-75 months) follow-up 
At mid-term follow-up 102 patients underwent endoscopy. In the APC group a further 
3 patients were withdrawn (death from pneumonia-1, death from small cell lung 
cancer – 1, HGD requiring esophagectomy – 1,). One patient also developed LGD in 
the APC group. Follow-up for 5 other patients had not reached 42 months. In the 
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surveillance group 6 were withdrawn or reached the study end point (refused 
endoscopy - 1, could not be contacted - 1, died of respiratory failure 1, developed 
HGD – 3 [treated by APC - 1, esophagectomy – 1, ongoing endoscopy surveillance – 
1]). In the surveillance group 1 patient who was diagnosed with LGD at short term 
follow-up continued to have LGD and 4 other patients also developed new LGD. 
Follow-up for 2 patients did not reach the 42 months time point. Hence, dysplasia was 
identified at mid-term follow-up in 2/49 patients in the APC group vs. 8/53 in the 
surveillance group (P=0.0947), with HGD developing in 1/49 vs. 3/53 respectively 
(P=0.619) 
 
Of the 49 patients allocated to APC ablation, 33 (67.3%) had at least 95% reduction in 
the area of Barrett’s esophagus mucosa vs. 2 (3.8%) of 53 in the surveillance group 
(p<0.0001).The length of Barrett’s esophagus was stable in the APC group from short 
to mid-term follow-up. However, there was a mean decrease of 1.1 cm in Barrett’s 
esophagus length in the surveillance group (p=0.04). 
 
Long term (> 84 months) 
At long term follow-up 59 patients underwent endoscopy. In the APC group, 1 further 
patient was withdrawn due to the development of esophageal varices, 1 died from 
pancreatic cancer, 1 failed to attend endoscopy follow-up, and in 14 patients follow-
up was < 84 months. In the surveillance group, 2 were withdrawn from study due to 
ill health, 3 moved to another Australian State and were lost to endoscopy follow-up 
within the trial, 1 died from pancreatic cancer and 21 had been enrolled < 84 months. 
In the APC group 21 (65.6%) of 32 patients maintained at least 95% reduction of 
Barrett’s esophagus compared to 4 (14.8%) of 27 patients in the surveillance group 
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(p<0.0001)). The length of Barrett’s esophagus was stable in both groups, compared 
to medium term follow-up, with the length 2.4 cm shorter at late follow-up in the 
APC group compared to the surveillance group (p<0.0001). No patient developed 
HGD or cancer between mid- and longer term follow-up. In the surveillance group 1 
new patient developed LGD and in the APC group no patients developed LGD 
between mid- and longer term follow-up. 
 
Overall detection of dysplasia is summarized in Table 2. Across both mid- and longer 
term follow-up time points, dysplasia developed in 2 patients in the APC group (LGD 
- 1, HGD - 1) vs. 9 patients in the surveillance group (LGD – 6, HGD 3). Thus for all 
grades of dysplasia p=0.054 and for HGD, p=0.619. No patient developed esophageal 
adenocarcinoma in either group.  
 
“Surgical” vs. “Medical” trial 
In the “Surgical” trial the study population was 4.4 years younger than the “Medical” 
trial (p=0.012), the length of Barrett’s esophagus was 1.4 cm longer (p= 0.030), and 
the APC group underwent 1 more ablation treatment session, compared to the medical 
trial (mean 3.2 vs. 2.2, p=0.008). There was no difference in the extent of ablation 
achieved in both groups, with at least 95% ablation in 62/63 patients. At short, mid- 
and long term, there was no significant difference in the proportion of patients 
maintaining at least 95% regression of their Barrett’s esophagus (p=0.476, p=1.000, 
p=0.283), and in both trials the length of Barrett’s esophagus in the control groups 
was stable across the entire follow-up. LGD was identified in the surveillance groups 
in both trials. In the medical trial, LGD did not develop during follow-up in the APC 
group, while it did occur in the surgical trial at mid term follow-up in one patient. 
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 Complications 
Three patients in the APC group of the surgical trial and another 3 in the APC group 
of the medical trial developed strictures requiring endoscopic dilation. In the medical 
trial 1 patient in the APC group developed impaired esophageal motility 6 years post-
ablation and was diagnosed with achalasia.   
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DISCUSSION  
APC treatment achieved regression of greater than 95% of the Barrett’s esophagus 
mucosa in 61 of 63 treated patients in this study. In 36 of these patients 
histopathological complete regression was also achieved. Further, the results achieved 
by APC did not differ between patients treated by medical vs. surgical antireflux 
therapy, with more than 95% regression accomplished in all but one patient in each 
group. Short, medium and long-term outcomes were analysed to enable multiple 
comparisons between the treatment and non-treatment groups and to put the results 
into a relevant context with other reported studies. The short and medium term 
outcomes following APC ablation therapy support the results from our earlier reports 
which included a smaller patient cohort, with shorter follow-up[9-11].   
 
Other studies reporting outcomes following APC ablation have reported relatively 
shorter follow-up than our study[12-15].  Ferraris et al. reported that Barrett’s 
esophagus recurred in 18% of patients at 36 months follow-up after APC ablation[12]. 
Pinotti et al reported maintenance of complete eradication of Barrett’s esophagus 
following APC in 94.7% of patients at 17 months follow-up[13], and 87% at mean 
follow-up of 31.9 months[14], whereas Sharma et al. reported that 63% of patients 
treated with APC had no recurrence of Barrett’s esophagus mucosa at two years 
follow-up[15] In our study the rates of complete eradication appeared to be somewhat 
lower at mid-term follow-up, but this might represent the longer follow-up interval of 
42-75 months. 
 
Our study reports significantly longer follow-up following ablation of Barrett’s 
esophagus than previous studies, and included a randomization generated control 
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group. It also stratified patients according to the method of reflux control i.e. 
fundoplication vs. high dose PPIs. We have also shown that at longer term follow-up 
the majority of the APC group maintained regression of more than 95% of their 
Barrett’s esophagus. This finding was largely due to the longer term results from the 
“Surgical group”. In the “Medical group” this regression was not as pronounced, 
although fewer patients in this part of the study had reached late follow-up.  
 
When establishing these trials, it was hoped that APC ablation would prevent the 
development of dysplasia and cancer. However, the outcome data does not fully 
support this, with HGD arising in both the APC group and the surveillance group in 
the “Surgical trial” at mid-term follow-up. While dysplasia (HGD and LGD) occurred 
more commonly in the surveillance arm, it was not statistically significantly less 
frequent in the APC group, although with a p value of 0.054 the clear possibility of a 
type 2 error remains. Ongoing surveillance enabling more patients to reach longer 
term follow-up will be undertaken to explore this outcome further. The occurrence 
after ablation certainly demonstrates the need for ongoing follow-up of both groups.  
 
In general, anti-reflux surgery has not been shown to prevent progression of Barrett’s 
esophagus to cancer[1,16,17].   In our study, patients who underwent fundoplication 
for reflux control might have had more severe reflux than those continuing on PPI 
therapy, but this was not formally evaluated between the surgical and medical arms of 
the trial, as randomization was within 2 defined cohorts, with no attempt considered 
to randomize to medical vs. surgical antireflux therapy. Further, we did not perform 
24 hour pH monitoring in a structured protocol driven manner during follow-up, so 
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the possibility that patients who progressed to HGD did not have adequate reflux 
control remains. 
 
Interestingly, in the surveillance arm of the “Surgical trial” some regression of 
Barrett’s esophagus continued to evolve as follow-up lengthened, while the length of 
Barrett’s esophagus in the surveillance arm of the “Medical trial” remained the same 
across the whole study period. This raises the possibility that antireflux surgery might 
be followed by spontaneous resolution of Barrett’s esophagus, at least to some extent, 
over the long term. The length of Barrett’s esophagus has been shown to be a risk 
factor for progression to adenocarcinoma[18], and for this reason a reduction in length 
in the control group could be seen to be beneficial, although as discussed above, 
progression to HGD was not prevented. 
 
In our study 7 patients (10.9% of all patients in the APC group) presented with a 
complication after ablation treatment, four patients in the surgical group and three in 
the medical group. Most of the complications occurred several years after therapy, 
most commonly a late esophageal stricture. These strictures were easily resolved with 
endoscopic dilatation.  In other studies complications appeared to occur earlier[13,15] 
In our study the complication rate seems lower than in other APC studies, which 
report complications in 52.6%[13] and 21%[15] of cases, including post-procedure 
pain. However, short term pain was not taken into account in our study. While the rate 
of complications is low, it would appear to be higher than that seen with RFA. In a 
meta-analysis of RFA studies[19], a stricture rate of 2.2% after an average of 2.1 
treatments was reported. However, RFA was not available, whereas APC was a 
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readily available technique for Barrett’s esophagus ablation at the inception of our 
study. 
 
Other ablative therapies have also been reported to be effective for Barrett’s 
esophagus. Photodynamic therapy (PDT) has been reported to achieve endoscopic 
complete regression in 50-90%[20-23] and Ackroyd et al. reported that ablation was 
maintained at median follow-up of 53 months[20]. Their results were similar to the 
endoscopic complete regression maintained in 67% in the APC group in our study. 
Radiofrequency ablation (RFA) has been reported to achieve complete remission in 
98% at 30 months follow-up in one study[24]24, although another study reported that 
in 8.5% of patients whose Barrett’s esophagus was completely eradicated by RFA, 
dysplasia was detected at one year follow-up[25]. Long term outcomes following 
RFA are yet to be reported.  
 
Potential limitations of our study include the lack of blinding of the initial (treating) 
endoscopist and the patient to the treatment given. However multiple endoscopists 
performed the subsequent surveillance biopsies, reported the length of Barrett’s 
esophagus in a standardized fashion, and took biopsies from the same levels as had 
been taken at the index endoscopy, and the surveillance endoscopists were blinded to 
whether APC had been performed. Another limitation is that follow-up was not 
100%complete, although it was high across the duration of the study. Only 8 of 129 
patients were actually lost to follow up (2 APC patients and 6 surveillance patients). 
However, a further 20 patients (12 APC and 8 surveillance) were withdrawn and did 
not contribute to longer term follow-up, because of either ill health/natural mortality 
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or progression to high grade dysplasia. There is no obvious bias introduced into the 
results by this withdrawal.  
 
This study has shown that APC reduced the extent of Barrett’s esophagus, and the 
majority of patients have much less Barrett’s esophagus mucosa at mid- to longer 
term follow-up, although some regeneration of Barrett’s esophagus does occur in 
some patients. The efficacy of ablation seems to be similar in patients who underwent 
anti-reflux surgery before ablation vs. those using PPIs. Whilst there was some 
reduction in the length of Barrett’s esophagus in post-fundoplication patients who 
were then enrolled to surveillance endoscopy rather than ablation, this effect was not 
evident in patients managed only with PPI medication. However, anti-reflux surgery 
did not prevent progression to HGD, and the results of our study do not support the 
use of antireflux surgery to prevent esophageal cancer.  
 
The results from our trial do not provide convincing support for the routine APC 
ablation of Barrett’s esophagus. Longer term outcomes from alternative ablative 
therapies such as RFA are awaited to see whether its outcomes resemble the results of 
this study. Nevertheless, APC ablation of Barrett’s esophagus does result in a 
reasonably stable length of neosquamous epithelium at follow-up of 7 or more years, 
and with even longer term follow up it may be found to reduce rates of progression to 
dysplasia.  
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 Table 1 Mean length of Barrett’s Esophagus at initial assessment and follow-up 
 
 APC group -
Barrett’s Length 
in cm (range) 
Surveillance 
group -Barrett’s 
Length in cm 
(range) 
P-value  
All patients   
 
Initial endoscopy 4.3 (1-13) 4.2 (1-16) 0.796 
Short term * 0.8 (0-11) 4.2 (0-13) <0.0001 
Mid term † 0.8 (0-9) 3.1 (0-10) <0.0001 
Long term ‡ 0.7 (0-2) 2.7 (0-8) <0.0001 
Surgical trial    
Initial endoscopy 5.1 (1-13) 4.4 (1-16) 0.344 
Short term * 0.9 (0-11) 3.9 (0-13) <0.0001 
Mid term † 0.8 (0-3) 2.9 (0-10) <0.0001 
Long term ‡ 0.7 (0-2) 2.4 (0-7) 0.0003 
Medical trial    
Initial endoscopy 3.2 (1-11) 3.9 (1-12) 0.259 
Short term * 0.7 (0-4) 4.6 (1-12) <0.0001 
Mid term † 0.7 (0-9) 3.4 (1-8) =0.0001 
Long term ‡ 0.5 (0-1) 3.0 (0-8) 0.004 
 
* Twelve months 
† 3.5-6 years 
‡ 7-11 years 
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Table 2 Progression to dysplasia or esophageal cancer 
 
 n APC group n Control group 
Overall     
Initial endoscopy 64 LGD: 3  65 LGD: 3  
Short term 56 0 61 LGD: 4  
Mid term 50 LGD: 1 
HGD: 1 
56 LGD: 5  
HGD: 3*†  
Long term 32 0 27 LGD: 1  
Surgical group     
Initial endoscopy 37 LGD: 1 33 LGD: 1 
Short term 32 0 33 LGD: 1 
Mid term 27 LGD: 1 
HGD: 1 
31 LGD: 3 
HGD: 3 
Long term 19 0 16 0 
Medical group     
Initial endoscopy 27 LGD: 2 32 LGD: 2 
Short term 24 0 28 LGD: 3 
Mid term 23 0 25 LGD: 2 
Long term 13 0 11 LGD: 1 
 
LGD = low grade dysplasia, HGD = high grade dysplasia 
 
 
†All patients with HGD were withdrawn from study as they had definitive treatment 
of their HGD. No patient developed HGD between mid- and long term follow-up. 
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Table 3 Extent of Barrett Esophagus at follow-up 
 
 
Post-
APC  
Short- 
term*  
Mid 
term† 
 Long 
term‡ 
 
 
APC 
Group 
Surveillance 
Group 
APC 
Group 
Surveillance 
Group 
APC 
Group 
Surveillance 
Group 
APC 
Group 
Surveillance 
Group 
All patients n = 63 n=65 n = 56 n = 61 n = 49 n = 53 n = 32 n = 27 
Endoscopic and 
histological 
complete 
regression 
36 
(57.1%) N/A 
21 
(37.5%) 2 (3.3%) 
18 
(36.7%) 1 (1.9%) 
6 
(18.8%) 2 (7.4%) 
Endoscopic 
regression 95%-
99%  
25 
(34.9%) N/A 
26 
(46.4%) 0 (0%) 
15 
(30.6%) 1 (1.9%) 
15 
(46.9%) 2 (7.4%) 
Endoscopic 
regression <95% 2 (3.2%) N/A 
9 
(16.1%) 59 (96.7%) 
16 
(32.6%) 51 (96.2%) 
11 
(34.4%) 23 (85.2%) 
Surgical trial n = 36 n=33 n = 32 n = 33 n = 26 n = 28 n = 19 n = 16 
Endoscopic and 
histological 
complete 
regression 
20 
(55.6%) N/A 
12 
(37.5%) 2 (6.1%) 
11 
(42.3%) 1 (3.6%) 
4 
(21.1%) 1 (6.3%) 
Endoscopic 
regression 95%-
99%  
15 
(41.7%) N/A 
16 
(50.0%) 0 (0%) 6 (23.1%) 1 (3.6%) 
10 
(52.6%) 1 (6.3%) 
Endoscopic 
regression <95% 1 (2.8%) N/A 
4 
(12.5%) 31 (93.9%) 9 (34.6%) 26 (92.8%) 
5 
(26.3%) 14 (87.5%) 
Medical trial n =27 n=32 n = 24 n =28 n = 23 n = 25 n = 13 n = 11 
Endoscopic and 
histological 
complete 
regression 
16 
(59.3%) N/A 
9 
(37.5%) 0 (0%) 7 (30.4%) 0 (0%) 
2 
(15.4%) 1 (9.1%) 
Endoscopic 
regression 95%-
99%  
10 
(37.0%) N/A 
10 
(41.7%) 0 (0%) 9 (39.1%) 0 (0%) 
5 
(38.5%) 1 (9.1%) 
Endoscopic 
regression <95% 1 (3.7%) N/A 
5 
(20.8%) 28 (100%) 7 (30.4%) 25 (100%) 
6 
(46.2%) 9 (81.8%) 
 
* Twelve months follow-up 
† 3.5-6 years follow-up 
‡ 7-11 years follow-up 
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FIGURE LEGEND 
 
Figure 1 CONSORT diagram for randomized trials 
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